Data ExclusivityRegulatory Data Protection, Data Protection Period
A period during which regulators cannot rely on an originator's trial data to approve a generic or biosimilar competitor, distinct from patent protection.
Terms for how medicine prices are set and negotiated and how patients gain access to new treatments.
A period during which regulators cannot rely on an originator's trial data to approve a generic or biosimilar competitor, distinct from patent protection.
A pricing strategy selling the same product at different prices in different markets, typically reflecting differences in ability to pay.
The setting and negotiation of medicine prices and payments across a specified product, purchaser, market and point in the supply chain.